Literature DB >> 28592707

Endothelial Nitric Oxide Synthase-Independent Pleiotropic Effects of Pitavastatin Against Atherogenesis and Limb Ischemia in Mice.

Takeshi Mitsuhashi1, Ryoko Uemoto2, Kazue Ishikawa3, Sumiko Yoshida4, Yasumasa Ikeda5, Shusuke Yagi6, Toshio Matsumoto7, Masashi Akaike3, Ken-Ichi Aihara2.   

Abstract

AIM: Statins have a protective impact against cardiovascular diseases through not only lipid-lowering effects but also pleiotropic effects, including activation of the endothelial nitric oxide synthase (eNOS) system. We aimed to clarify the protective effects of a statin against atherogenesis and ischemia in eNOS-/- mice.
METHODS: Study 1. eNOS-/- Apolipoprotein E (ApoE)-/- mice were treated with a vehicle or pitavastatin (0.3 mg/kg/day) for 4 weeks. Study 2. eNOS-/- mice were also treated with a vehicle or the same dose of pitavastatin for 2 weeks prior to hind-limb ischemia.
RESULTS: In Study 1, pitavastatin attenuated plaque formation and medial fibrosis of the aortic root with decreased macrophage infiltration in eNOS-/- ApoE-/- mice. PCR array analysis showed reductions in aortic gene expression of proatherogenic factors, including Ccl2 and Ccr2 in pitavastatin-treated double mutant mice. In addition, pitavastatin activated not only atherogenic p38MAPK and JNK but also anti-atherogenic ERK1/2 and ERK5 in the aorta of the double mutant mice. In Study 2, pitavastatin prolonged hind-limb survival after the surgery with increased BCL2-to-BAX protein ratio and inactivated JNK. Enhanced expression of anti-apoptotic genes, including Vegf, Api5, Atf5, Prdx2, and Dad1, was observed in the ischemic limb of pitavastatin-treated eNOS-/- mice. Furthermore, pitavastatin activated both aortic and skeletal muscle AMPK in the eNOS-deficient vascular injury models.
CONCLUSION: Pitavastatin exerts eNOS-independent protective effects against atherogenesis and hind-limb ischemia in mice, which may occur via modifications on key molecules such as AMPK and diverse molecules.

Entities:  

Keywords:  Atherogenesis; Ischemia; Pitavastatin; Pleiotropic effect; eNOS

Mesh:

Substances:

Year:  2017        PMID: 28592707      PMCID: PMC5770225          DOI: 10.5551/jat.37747

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  49 in total

1.  AMP-activated protein kinase suppresses endothelial cell inflammation through phosphorylation of transcriptional coactivator p300.

Authors:  Yuan Zhang; Jian Qiu; Xiaoming Wang; Yuhua Zhang; Min Xia
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-09-22       Impact factor: 8.311

2.  HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome.

Authors:  Nerea Hermida; Andreas Markl; Julien Hamelet; Tim Van Assche; Annelies Vanderper; Paul Herijgers; Marc van Bilsen; Denise Hilfiker-Kleiner; Gauthier Noppe; Christophe Beauloye; Sandrine Horman; Jean-Luc Balligand
Journal:  Cardiovasc Res       Date:  2013-03-29       Impact factor: 10.787

3.  Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury.

Authors:  Shusuke Yagi; Masashi Akaike; Ken-ichi Aihara; Kazue Ishikawa; Takashi Iwase; Yasumasa Ikeda; Takeshi Soeki; Sumiko Yoshida; Yuka Sumitomo-Ueda; Toshio Matsumoto; Masataka Sata
Journal:  Hypertension       Date:  2010-03-01       Impact factor: 10.190

4.  Atorvastatin and pitavastatin enhance lipoprotein lipase production in L6 skeletal muscle cells through activation of adenosine monophosphate-activated protein kinase.

Authors:  Masahiro Ohira; Kei Endo; Atsuhito Saiki; Yoh Miyashita; Kensuke Terai; Takeyoshi Murano; Fusako Watanabe; Ichiro Tatsuno; Kohji Shirai
Journal:  Metabolism       Date:  2012-04-19       Impact factor: 8.694

5.  Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure.

Authors:  Masaaki Hayashi; Sung-Woo Kim; Kyoko Imanaka-Yoshida; Toshimichi Yoshida; E Dale Abel; Brian Eliceiri; Young Yang; Richard J Ulevitch; Jiing-Dwan Lee
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

6.  Postnatal shifts in ischemic tolerance and cell survival signaling in murine myocardium.

Authors:  Norman Y Liaw; Louise See Hoe; Freya L Sheeran; Jason N Peart; John P Headrick; Michael M H Cheung; Salvatore Pepe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-09-25       Impact factor: 3.619

7.  Cardioprotective effects of pitavastatin on cardiac performance and remodeling in failing rat hearts.

Authors:  Naohiko Kobayashi; Hiroshi Takeshima; Hiromichi Fukushima; Wataru Koguchi; Yasuko Mamada; Hisato Hirata; Yoshifumi Machida; Motoo Shinoda; Noriko Suzuki; Fumie Yokotsuka; Kyoko Tabei; Hiroaki Matsuoka
Journal:  Am J Hypertens       Date:  2008-11-27       Impact factor: 2.689

8.  The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.

Authors:  T J Anderson; I T Meredith; A C Yeung; B Frei; A P Selwyn; P Ganz
Journal:  N Engl J Med       Date:  1995-02-23       Impact factor: 91.245

9.  Macrophage Phenotype Modulation by CXCL4 in Atherosclerosis.

Authors:  Christian A Gleissner
Journal:  Front Physiol       Date:  2012-01-13       Impact factor: 4.566

10.  Therapeutic Potential of the Nitrite-Generated NO Pathway in Vascular Dysfunction.

Authors:  Michael Madigan; Brian Zuckerbraun
Journal:  Front Immunol       Date:  2013-07-02       Impact factor: 7.561

View more
  1 in total

Review 1.  The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review.

Authors:  Qinchao Wu; Baochen Bai; Chao Tian; Daisong Li; Haichu Yu; Bingxue Song; Bing Li; Xianming Chu
Journal:  Cardiovasc Drugs Ther       Date:  2021-04-13       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.